SEARCH

SEARCH BY CITATION

References

  • 1
    Simala-Grant JL, Taylor DE. Molecular biology methods for the characterization of Helicobacter pylori infections and their diagnosis. APMIS 2004; 112: 88697.
  • 2
    Ahmed N, Sechi LA. Helicobacter pylori and gastroduodenal pathology: new threats of the old friend. Ann Clin Microbiol Antimicrob 2005; 4: 1.
  • 3
    Perez-Perez GI, Rothenbacher D, Brenner H. Epidemiology of Helicobacter pylori infection. Helicobacter 2004; 9: 16.
  • 4
    Loughlin MF. Novel therapeutic targets in Helicobacter pylori. Expert Opin Ther Targets 2003; 7: 72535.
  • 5
    Malfertheiner P, Megraud F, O’Morain C, et al. Current concepts in the management of Helicobacter pylori infection – the Maastricht III Consensus Report. Gut 2007; 17: 0313.
  • 6
    Fischbach LA, Goodman KJ, Feldman M, Aragaki C. Sources of variation of Helicobacter pylori treatment success in adults worldwide: a meta-analysis. Int J Epidemiol 2002; 31: 12839.
  • 7
    Lopez-Brea M, Martinez MJ, Domingo D, Alarcon T. A 9-year study of clarithromycin and metronidazole resistance in Helicobacter pylori from Spanish children. J Antimicrobial Chemother 2001; 48: 2957.
  • 8
    Masuda H, Hiyama T, Yoshihara M, Tanaka S, Haruma K, Chayama K. Characteristics and trends of clarithromycin-resistant Helicobacter pylori isolates in Japan over a decade. Pathobiology 2004; 71: 15963.
  • 9
    Eun CS, Han DS, Park JY, et al. Changing pattern of antimicrobial resistance of Helicobacter pylori in Korean patients with peptic ulcer diseases. J Gastroenterol 2003; 38: 51921.
  • 10
    Crone J, Granditsch G, Huber WD, et al. Helicobacter pylori in children and adolescents: increase of primary clarithromycin resistance. J Pediatr Gastroenterol Nutr 2003; 36: 36871.
  • 11
    Glupczynski Y. Antimicrobial resistance in Helicobacter pylori: a global overview. Acta Gastroenterol Belg 1998; 61: 35766.
  • 12
    Osato MS, Reddy R, Reddy SG, Penland RL, Malaty HM, Graham DY. Pattern of primary resistance of Helicobacter pylori to metronidazole or clarithromycin in the United States. Arch Int Med 2001; 161: 121720.
  • 13
    Meyer JM, Silliman NP, Wang W, et al. Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993-1999. Ann Intern Med 2002; 136: 1324.
  • 14
    Megraud F. H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004; 53: 137484.
  • 15
    Sherif M, Mohran Z, Fathy H, Rockabrand DM, Rozmajzl PJ, Frenck RW. Universal high-level primary metronidazole resistance in Helicobacter pylori isolated from children in Egypt. J Clin Microbiol 2004; 42: 48324.
  • 16
    Al-Qurashi AR, El-Morsy F, Al-Quorain AA. Evolution of metronidazole and tetracycline susceptibility pattern in Helicobacter pylori at a hospital in Saudi Arabia. Int J Antimicrob Agents 2001; 17: 2336.
  • 17
    Nahar S, Mukhopadhyat AK, Khan R, et al. Antimicrobial susceptibility of Helicobacter pylori strains isolated in Bangladesh. J Clin Microbiol 2004; 42: 48568.
  • 18
    Thyagarajan SP, Ray P, Das BK, et al. Geographical difference in antimicrobial resistance pattern of Helicobacter pylori clinical isolates from Indian patients: Multicentric study. J Gastroenterol Hepatol 2003; 18: 13738.
  • 19
    Prazeres Magalhaes P, De Magalhaes Queiroz DM, Campos Barbosa DV, et al. Helicobacter pylori primary resistance to metronidazole and clarithromycin in Brazil. Antimicrob Agents Chemother 2002; 46: 20213.
  • 20
    Masaoka T, SuzukiKurabayashi HK, Kamiya AG, Ishii H. Second-line treatment of Helicobacter pylori infection after dilution agar methods and PCR-RFLP analysis. Aliment Pharmacol Ther 2004; 20 (Suppl. 1): 6873.
  • 21
    Peitz U, Hackelsberger A, Malfertheiner P. A practical approach to patients with refractory Helicobacter pylori infection, or who are re-infected after standard therapy. Drugs 1999; 57: 90520.
  • 22
    Buckley MJ, Xia HX, Hyde DM, Keane CT, O’Morain CA. Metronidazole resistance reduces efficacy of triple therapy and leads to secondary clarithromycin resistance. Dig Dis Sci 1997; 42: 21115.
  • 23
    Rothman KJ, Greenland S. Modern Epidemiology, 2nd edn. Philadelphia, PA: Lippincott-Raven, 1998.
  • 24
    Goldstein H. Multilevel Statistical Models, 2nd edn. London: Edward Arnold, 1995.
  • 25
    Goldstein H, Rasbach J, Plewis I, et al. A User’s Guide to MLWIN. Version 1. University of London, UK: Multilevel Models Project, Institute of Education, 1998.
  • 26
    Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 62934.
  • 27
    Glupczynski Y, Burette A. Eradicating Helicobacter pylori. Lancet 1992; 339: 545.
  • 28
    Logan RP, Gummett PA, Misiewicz JJ, Karim QN, Walker MM, Baron JH. One week eradication regimen for Helicobacter pylori. Lancet 1991; 338: 124952.
  • 29
    Midolo PD, Lambert JR, Turnidge J. Metronidazole resistance: a predictor of failure of Helicobacter pylori eradication by triple therapy. J Gastroenterol Hepatol 1996; 11: 2902.
  • 30
    Rautelin H, Kosunen TU, Seppala K. Eradicating Helicobacter pylori. Lancet 1992; 339: 55.
  • 31
    Savarino V, Zentilin P, Pivari M, et al. The impact of antibiotic resistance on the efficacy of three 7-day regimens against Helicobacter pylori. Aliment Pharmacol Ther 2000; 14: 893900.
  • 32
    Seppala K, Farkkila M, Nuutinen H, et al. Triple therapy of Helicobacter pylori infection in peptic ulcer. A 12-month follow-up study of 93 patients. Scand J Gastroenterol 1992; 27: 9736.
  • 33
    Bell GD, Powell KU, Burridge SM, et al. Helicobacter pylori eradication: efficacy and side effect profile of a combination of omeprazole, amoxycillin and metronidazole compared with four alternative regimens. Q J Med 1993; 86: 74350.
  • 34
    De Boer W, Driessen W, Jansz A, Tytgat G. Effect of acid suppression on efficacy of treatment for Helicobacter pylori infection. Lancet 1995; 345: 81720.
  • 35
    De Boer WA, Van Etten RJ, Schneeberger PM, Tytgat GN. A single drug for Helicobacter pylori infection: first results with a new bismuth triple monocapsule. Am J Gastroenterol 2000; 95: 6415.
  • 36
    Fraser AG, Moore L, Ali MR, Chua LE, Hollis B, Little SV. An audit of low dose triple therapy for eradication of Helicobacter pylori. N Z Med J 1996; 109: 2902.
  • 37
    Gisbert JP, Boixeda D, De Rafael L, Martin de Argila C, Bermejo F, Garcia Plaza A. The effect of “triple therapy” on the eradicating of H. pylori and the healing of a duodenal ulcer. The initial study and 6 months later. Rev Esp Enferm Dig 1995; 87: 1938.
  • 38
    Katelaris PH, Forbes GM, Talley NJ, Crotty B. A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: The QUADRATE Study. Gastroenterology 2002; 123: 17639.
  • 39
    Kung NN, Sung JJ, Yuen NW, et al. One-week ranitidine bismuth citrate versus colloidal bismuth subcitrate-based anti-Helicobacter triple therapy: a prospective randomized controlled trial. Am J Gastroenterol 1999; 94: 7214.
    Direct Link:
  • 40
    Lerang F, Moum B, Ragnhildstveit E, et al. A comparison between omeprazole-based triple therapy and bismuth-based triple therapy for the treatment of Helicobacter pylori infection: a prospective randomized 1-yr follow-up study. Am J Gastroenterol 1997; 92: 6538.
  • 41
    Lerang F, Moum B, Regnhildstveit E, Haug JB. Significance of metronidazole (MTZ) resistance in Helicobacter pylori eradication (HPE). Scand J Gastroenterol 1995; 30 (Suppl. 209): 28.
  • 42
    Lynch DA, Sobala GM, Gallacher B, Dixon MF, Axon AT. Effectiveness of a five times daily triple therapy regimen against Helicobacter pylori. J Antimicrob Chemother 1994; 33: 8779.
  • 43
    Roghani HS, Massarrat S, Pahlewanzadeh MR, Dashti M. Effect of two different doses of metronidazole and tetracycline in bismuth triple therapy on eradication of Helicobacter pylori and its resistant strains. Eur J Gastroenterol Hepatol 1999; 11: 70912.
  • 44
    Thijs JC, Van Zwet AA, Oey HB. Efficacy and side effects of a triple drug regimen for the eradication of Helicobacter pylori. Scand J Gastroenterol 1993; 28: 9348.
  • 45
    Bell GD, Powell K, Burridge SM, et al. Experience with ‘triple’ anti-Helicobacter pylori eradication therapy: side effects and the importance of testing the pre-treatment bacterial isolate for metronidazole resistance. Aliment Pharmacol Ther 1992; 6: 42735.
  • 46
    Adamek RJ, Pfaffenbach B, Szymanski C. Cure of H. pylori infection using a 7-day triple therapy combining pantoprazole with two antibiotics. Helicobacter 1998; 3: 20611.
  • 47
    Bayerdorffer E, Lonovics J, Dite P, et al. Efficacy of two different dosage regimens of omeprazole, amoxycillin and metronidazole for the cure of Helicobacter pylori infection. Aliment Pharmacol Ther 1999; 13: 163945.
  • 48
    Bell GD, Bate CM, Axon AT, et al. Addition of metronidazole to omeprazole/amoxycillin dual therapy increases the rate of Helicobacter pylori eradication: a double-blind, randomized trial. Aliment Pharmacol Ther 1995; 9: 51320.
  • 49
    Bhatia V, Ahuja V, Das B, Bal C, Sharma MP. Use of imidazole-based eradication regimens for Helicobacter pylori should be abandoned in North India regardless of in vitro antibiotic sensitivity. J Gastroenterol Hepatol 2004; 19: 61925.
  • 50
    Cayla R, Zerbib F, De Mascarel A, Megraud F, Lamouliatte H. Dual therapy with high dose of omeprazole versus triple therapy using omeprazole in combination with two antibiotics for H. pylori eradication: Results of a randomized controlled trial among 100 patients. Am J Gastroenterol 1994; 89: 1366.
  • 51
    Bell GD, Powell KU, Burridge SM, et al. Rapid eradication of Helicobacter pylori infection. Aliment Pharmacol Ther 1995; 9: 416.
  • 52
    Chuang CH, Sheu BS, Huang AH, Yang HB, Wu JJ. Vitamin C and E supplements to lansoprazole-amoxicillin-metronidazole triple therapy may reduce the eradication rate of metronidazole-susceptible Helicobacter pylori infection. Helicobacter 2002; 7: 3106.
  • 53
    Ching CK, Leung KP, Yung RW, et al. Prevalence of metronidazole resistant Helicobacter pylori strains among Chinese peptic ulcer disease patients and normal controls in Hong Kong. Gut 1996; 38: 6758.
  • 54
    Fock KM, Chelvam P, Lim SG. Triple therapy in the eradication of Helicobacter pylori in patients with duodenal ulcer disease: results of a multicentre study in South-East Asia. South-East Asia Multicenter Study Group. Aliment Pharmacol Ther 2000; 14: 22531.
  • 55
    Goh KL, Parasakthi N, Chuah SY, Toetsch M. Combination amoxycillin and metronidazole with famotidine in the eradication of Helicobacter pylori–a randomized, double-blind comparison of a three times daily and twice daily regimen. Eur J Gastroenterol Hepatol 1997; 9: 10915.
  • 56
    Hsu CC, Chen JJ, Hu TH, Lu SN, Changchien CS. Famotidine versus omeprazole, in combination with amoxycillin and tinidazole, for eradication of Helicobacter pylori infection. Eur J Gastroenterol Hepatol 2001; 13: 9216.
  • 57
    Katelaris PH, Adamthwaite D, Midolo P, Yeomans ND, Davidson G, Lambert J. Randomized trial of omeprazole and metronidazole with amoxycillin or clarithromycin for Helicobacter pylori eradication, in a region of high primary metronidazole resistance: the HERO study. Aliment Pharmacol Ther 2000; 14: 7518.
  • 58
    Koivisto TT, Rautelin HI, Voutilainen ME, Heikkinen MT, Koskenpato JP, Farkkila MA. First-line eradication therapy for Helicobacter pylori in primary health care based on antibiotic resistance: results of three eradication regimens. Aliment Pharmacol Ther 2005; 21: 77382.
  • 59
    Lehmann FS, Drewe J, Terracciano L, Beglinger C. Effect of ornidazole and clarithromycin resistance on eradication of Helicobacter pylori in peptic ulcer disease. Aliment Pharmacol Ther 2000; 14: 3059.
  • 60
    Lerang F, Moum B, Haug JB, et al. Highly effective twice-daily triple therapies for Helicobacter pylori infection and peptic ulcer disease: does in vitro metronidazole resistance have any clinical relevance? Am J Gastroenterol 1997; 92: 24853.
  • 61
    Misiewicz JJ, Harris AW, Bardhan KD, et al. One week triple therapy for Helicobacter pylori: a multicentre comparative study. Lansoprazole Helicobacter Study Group. Gut 1997; 41: 7359.
  • 62
    Miyaji H, Azuma T, Ito S, et al. Susceptibility of Helicobacter pylori isolates to metronidazole, clarithromycin and amoxycillin in vitro and in clinical treatment in Japan. Aliment Pharmacol Ther 1997; 11: 11316.
  • 63
    Pilotto A, Leandro G, Franceschi M, et al. The effect of antibiotic resistance on the outcome of three 1-week triple therapies against Helicobacter pylori. Aliment Pharmacol Ther 1999; 13: 66773.
  • 64
    Realdi G, Dore MP, Piana A, et al. Pretreatment antibiotic resistance in Helicobacter pylori infection: results of three randomized controlled studies. Helicobacter 1999; 4: 10612.
  • 65
    Thijs JC, Van Zwet AA, Thijs WJ, Van der Wouden EJ, Kooy A. One-week triple therapy with omeprazole, amoxycillin and tinidazole for Helicobacter pylori infection: the significance of imidazole resistance. Aliment Pharmacol Ther 1997; 11: 3059.
  • 66
    Veldhuyzen van Zanten S, Hunt RH, Cockeram A, et al. Adding once-daily omeprazole 20 mg to metronidazole/amoxicillin treatment for Helicobacter pylori gastritis: a randomized, double-blind trial showing the importance of metronidazole resistance. Am J Gastroenterol 1998; 93: 510.
  • 67
    Bago J, Halle ZB, Strinic D, et al. The impact of primary antibiotic resistance on the efficacy of ranitidine bismuth citrate- vs. omeprazole-based one-week triple therapies in H. pylori eradication – a randomised controlled trial. Wien Klin Wochenschr 2002; 114: 44853.
  • 68
    Bardhan KD, Morton D, Slater DN, et al. Pantoprazole-based 10-day triple therapy is effective in Helicobacter pylori eradication. Aliment Pharmacol Ther 1998; 12: 1859.
  • 69
    Bazzoli F, Zagari M, Pozzato P, et al. Evaluation of short-term low-dose triple therapy for the eradication of Helicobacter pylori by factorial design in a randomized, double-blind, controlled study. Aliment Pharmacol Ther 1998; 12: 43945.
  • 70
    Bochenek WJ, Peters S, Fraga PD, et al. Eradication of Helicobacter pylori by 7-day triple-therapy regimens combining pantoprazole with clarithromycin, metronidazole, or amoxicillin in patients with peptic ulcer disease: results of two double-blind, randomized studies. Helicobacter 2003; 8: 62642.
  • 71
    Eisig JN, Andre SB, Silva FM, Hashimoto C, Moraes-Filho JP, Laudanna AA. The impact of Helicobacter pylori resistance on the efficacy of a short course pantoprazole based triple therapy. Arq Gastroenterol 2003; 40: 5560.
  • 72
    Ellenrieder V, Boeck W, Richter C, Marre R, Adler G, Glasbrenner B. Prevalence of resistance to clarithromycin and its clinical impact on the efficacy of Helicobacter pylori eradication. Scand J Gastroenterol 1999; 34: 7506.
  • 73
    Goh KL, Parasakthi N, Chuah SY, Cheah PL, Lo YL, Chin SC. Comparison of two 1-week low-dose omeprazole triple therapies – optimal treatment for Helicobacter pylori infection? Aliment Pharmacol Ther 1997; 11: 11158.
  • 74
    Gschwantler M, Dragosics B, Schutze K, et al. Famotidine versus omeprazole in combination with clarithromycin and metronidazole for eradication of Helicobacter pylori–a randomized, controlled trial. Aliment Pharmacol Ther 1999; 13: 10639.
  • 75
    Harris AW, Pryce DI, Gabe SM, et al. Lansoprazole, clarithromycin and metronidazole for seven days in Helicobacter pylori infection. Aliment Pharmacol Ther 1996; 10: 10058.
  • 76
    Houben MH, Hensen EF, Rauws EA, et al. Randomized trial of omeprazole and clarithromycin combined with either metronidazole or amoxycillin in patients with metronidazole-resistant or -susceptible Helicobacter pylori strains. Aliment Pharmacol Ther 1999; 13: 8839.
  • 77
    Labenz J, Idstrom JP, Tillenburg B, Peitz U, Adamek RJ, Borsch G. One-week low-dose triple therapy for Helicobacter pylori is sufficient for relief from symptoms and healing of duodenal ulcers. Aliment Pharmacol Ther 1997; 11: 8993.
  • 78
    Lind T, Megraud F, Unge P, et al. The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology 1999; 116: 24853.
  • 79
    Liu WZ, Xiao SD, Shi Y, et al. Furazolidone-containing short-term triple therapies are effective in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 1999; 13: 31722.
  • 80
    Manes G, Pieramico O, Perri F, et al. Twice-daily standard dose of omeprazole achieves the necessary level of acid inhibition for Helicobacter pylori eradication. A randomized controlled trial using standard and double doses of omeprazole in triple therapy. Dig Dis Sci 2005; 0: 50443.
  • 81
    Miehlke S, Meining A, Lehn N, et al. Comparison of omeprazole, metronidazole and clarithromycin with omeprazole/amoxicillin dual-therapy for the cure of Helicobacter pylori infection. Digestion 1998; 59: 64650.
  • 82
    Neville PM, Everett S, Langworthy H, et al. The optimal antibiotic combination in a 5-day Helicobacter pylori eradication regimen. Aliment Pharmacol Ther 1999; 13: 497501.
  • 83
    Pohle T, Stoll R, Kirchner T, et al. Eradication of Helicobacter pylori with lansoprazole, roxithromycin and metronidazole – an open pilot study. Aliment Pharmacol Ther 1998; 12: 12738.
  • 84
    Poon SK, Chang CS, Su J, et al. Primary resistance to antibiotics and its clinical impact on the efficacy of Helicobacter pylori lansoprazole-based triple therapies. Aliment Pharmacol Ther 2002; 16: 2916.
  • 85
    Schwartz H, Krause R, Siepman N, et al. Seven-day triple therapy with lansoprazole, clarithromycin, and metronidazole for the cure of Helicobacter pylori infection: a short report. Helicobacter 1996; 1: 2515.
  • 86
    Toracchio S, Cellini L, Di Campli E, et al. Role of antimicrobial susceptibility testing on efficacy of triple therapy in Helicobacter pylori eradication. Aliment Pharmacol Ther 2000; 14: 163943.
  • 87
    Unge P. The OAC and OMC options. Eur J Gastroenterol Hepatol 1999; 11 (Suppl. 2): S917; discussion S23–24.
  • 88
    Wheeldon TU, Granstrom M, Hoang TT, Phuncarg DC, Nilsson LE, Sorberg M. The importance of the level of metronidazole resistance for the success of Helicobacter pylori eradication. Aliment Pharmacol Ther 2004; 19: 131521.
  • 89
    Wong BC, Wong WM, Wang WH, et al. One-week ranitidine bismuth citrate-based triple therapy for the eradication of Helicobacter pylori in Hong Kong with high prevalence of metronidazole resistance. Aliment Pharmacol Ther 2001; 15: 4039.
  • 90
    Wong WM, Gu Q, Wang WH, et al. Effects of primary metronidazole and clarithromycin resistance to Helicobacter pylori on omeprazole, metronidazole, and clarithromycin triple-therapy regimen in a region with high rates of metronidazole resistance. Clin Infect Dis 2003; 37: 8829.
  • 91
    Bago J, Galovic A, Belosic Halle Z, Bilic A, Bevanda M, Bago P. Comparison of the efficacy of 250 mg and 500 mg clarithromycin used with lansoprazole and amoxicillin in eradication regimens for Helicobacter pylori infection. Wien Klin Wochenschr 2004; 116: 4959.
  • 92
    Domingo D, Alarcon T, Vega AE, Garcia JA, Martinez MJ, Lopez-Brea M. Microbiological factors that influence the eradication of Helicobacter pylori in adults and children. Enfern Infect Microbiol Clin 2002; 20: 4314.
  • 93
    Ducons JA, Santolaria S, Guirao R, Ferrero M, Montoro M, Gomollon F. Impact of clarithromycin resistance on the effectiveness of a regimen for Helicobacter pylori: a prospective study of 1-week lansoprazole, amoxycillin and clarithromycin in active peptic ulcer. Aliment Pharmacol Ther 1999; 13: 77580.
  • 94
    Ecclissato C, Marchioretto MA, Mendonca S, et al. Increased primary resistance to recommended antibiotics negatively affects Helicobacter pylori eradication. Helicobacter 2002; 7: 539.
  • 95
    Gu Q, Xia H, Wang J, et al. Update on clarithromycin resistance in Helicobacter pylori in Hong Kong and its effect on clarithromycin-based triple therapy. Digestion 2006; 73: 1016.
  • 96
    Higuchi K, Maekawa T, Nakagawa K, et al. Efficacy and safety of Helicobacter pylori eradication therapy with omeprazole, amoxicillin and high-and low-dose clarithromycin in Japanese patients. Clin Drug Invest 2006; 26: 40314.
  • 97
    Kawabata H, Habu Y, Tomioka H, et al. Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin. Aliment Pharmacol Ther 2003; 17: 25964.
  • 98
    Kihira K, Satoh K, Saifuku K, et al. Rabeprazole, amoxycillin and low- or high-dose clarithromycin for cure of Helicobacter pylori infection. Aliment Pharmacol Ther 2000; 14: 10837.
  • 99
    Laine L, Hunt R, El-Zimaity H, Nguyen B, Osato M, Spenard J. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. Am J Gastroenterol 2003; 98: 5627.
    Direct Link:
  • 100
    Lamouliatte H, Samoyeau R, De Mascarel A, Megraud F. Double vs. single dose of pantoprazole in combination with clarithromycin and amoxycillin for 7 days, in eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. Aliment Pharmacol Ther 1999; 13: 152330.
  • 101
    Lee JH, Shin JH, Roe IH, et al. Impact of clarithromycin resistance on eradication of Helicobacter pylori in infected adults. Antimicrob Agents Chemother 2005; 49: 16003.
  • 102
    Miki I, Aoyama N, Sakai T, et al. Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan. Eur J Gastroenterol Hepatol 2003; 15: 2733.
  • 103
    Miwa H, Misawa H, Yamada T, Nagahara A, Ohtaka K, Sato N. Clarithromycin resistance, but not CYP2C-19 polymorphism, has a major impact on treatment success in 7-day treatment regimen for cure of H. pylori infection: a multiple logistic regression analysis. Dig Dis Sci 2001; 46: 244550.
  • 104
    Murakami K, Sato R, Okimoto T, et al. Eradication rates of clarithromycin-resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin. Aliment Pharmacol Ther 2002; 16: 19338.
  • 105
    Tankovic J, Lamarque D, Lascols C, Soussy CJ, Delchier JC. Clarithromycin resistance of Helicobacter pylori has a major impact on the efficacy of the omeprazole-amoxicillin-clarithromycin therapy. Pathol Biol (Paris) 2001; 49: 52833.
  • 106
    De Boer SY, V D Meeberg PC, Siem H, De Boer WA. Comparison of four-day and seven-day pantoprazole-based quadruple therapy as a routine treatment for Helicobacter pylori infection. Neth J Med 2003; 61: 21822.
  • 107
    De Boer WA, Van Etten RJ, Schade RW, Ouwehand ME, Schneeberger PM, Tytgat GN. 4-day lansoprazole quadruple therapy: a highly effective cure for Helicobacter pylori infection. Am J Gastroenterol 1996; 91: 177882.
  • 108
    De Boer WA, Van Etten RJ, Schneeberger PM. Four-day lansoprazole-quadruple therapy in the routine treatment of Helicobacter pylori infection. Neth J Med 1998; 52: 105.
  • 109
    De Boer WA, Van Etten RJ, Schade RW, et al. One-day intensified lansoprazole-quadruple therapy for cure of Helicobacter pylori infection. Aliment Pharmacol Ther 1997; 11: 10912.
  • 110
    De Boer WA, Driessen WM, Tytgat GN. Only four days of quadruple therapy can effectively cure Helicobacter pylori infection. Aliment Pharmacol Ther 1995; 9: 6338.
  • 111
    De Boer WA, Haeck PW, Otten MH, Mulder CJ. Optimal treatment of Helicobacter pylori with ranitidine bismuth citrate (RBC): a randomized comparison between two 7-day triple therapies and a 14-day dual therapy. Am J Gastroenterol 1998; 93: 11017.
  • 112
    Graham DY, Belson G, Abudayyeh S, Osato MS, Dore MP, El-Zimaity HM. Twice daily (mid-day and evening) quadruple therapy for H. pylori infection in the United States. Dig Liver Dis 2004; 36: 3847.
  • 113
    Graham DY, Hoffman J, El-Zimaity HM, Graham DP, Osato M. Twice a day quadruple therapy (bismuth subsalicylate, tetracycline, metronidazole plus lansoprazole) for treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 1997; 11: 9358.
  • 114
    Graham DY, Opekun AR, Belson G, El-Zimaity HM, Carlson MR. Novel bismuth-metronidazole-tetracycline triple-layer tablet for treatment of Helicobacter pylori. Aliment Pharmacol Ther 2005; 21: 1658.
  • 115
    O’Morain C, Borody T, Farley A, et al. Efficacy and safety of single-triple capsules of bismuth biskalcitrate, metronidazole and tetracycline, given with omeprazole, for the eradication of Helicobacter pylori: an international multicentre study. Aliment Pharmacol Ther 2003; 17: 41520.
  • 116
    Sung JJ, Chan FK, Wu JC, et al. One-week ranitidine bismuth citrate in combinations with metronidazole, amoxycillin and clarithromycin in the treatment of Helicobacter pylori infection: the RBC-MACH study. Aliment Pharmacol Ther 1999; 13: 107984.
  • 117
    Okada M, Nishimura H, Kawashima M, et al. A new quadruple therapy for Helicobacter pylori: influence of resistant strains on treatment outcome. Aliment Pharmacol Ther 1999; 13: 76974.
  • 118
    Van Der Wouden EJ, Thijs JC, Zwet AA, Kooy A, Kleibeuker JH. The influence of metronidazole resistance on the efficacy of ranitidine bismuth citrate triple therapy regimens for Helicobacter pylori infection. Aliment Pharmacol Ther 1999; 13: 297302.
  • 119
    Dore MP, Leandro G, Realdi G, Sepulveda AR, Graham DY. Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: a meta-analytical approach. Dig Dis Sci 2000; 45: 6876.
  • 120
    Megraud F. Basis for the management of drug-resistant Helicobacter pylori infection. Drugs 2004; 64: 1893904.
  • 121
    McLoughlin R, Racz I, Buckley M, O’Connor HJ, O’Morain C. Therapy of Helicobacter pylori. Helicobacter 2004; 9 (Suppl. 1): 428.
  • 122
    Fischbach LA, Van Zanten SV, Dickason J. Efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies: a meta-analysis. Aliment Pharmacol Ther 2004; 20: 112.
  • 123
    Pounder RE, Ng D. The prevalence of Helicobacter pylori infection in different countries. Aliment Pharmacol Ther 1995; 9 (Suppl. 2): 339.
  • 124
    Taylor DN, Blaser MH. The epidemiology of Helicobacter pylori infection. Epidemiol Rev 1991; 13: 4259.
  • 125
    Sack RB, Gyr K. Helicobacter pylori infections in the developing world. Summary of a workshop organized at the International Center for Diarrhoeal Disease Research, Bangladesh (ICDDR,B) from February 2 to 4, 1993. J Diarrheal Dis Res 1994; 12: 1445.
  • 126
    Fraser AG, Moore L, Hackett M, Hollis B. Helicobacter pylori treatment and antibiotic susceptibility: results of a five-year audit. Aust N Z J Med 1999; 29: 5126.